The Lp(a) Number Above 175 nmol/L: New NIH Data on Why Standard Treatment May Not Be Enough
A patient came to see me last month after his second heart attack. He’s 58. He’d been on a high-intensity statin for years. His LDL was right at goal. His blood pressure was controlled. He’d quit smoking a decade ago, exercised regularly, eaten well. By every standard cardiology metric I had to work with, he was doing what we’d asked of him. The second heart attack made no sense on paper. We sent the lab work I’d normally have ordered after the first one but didn’t. His lipoprotein(a) level came back at 247 nmol/L. That’s the conversation I want to write about today, because late-breaking data from the SCAI 2026 conference earlier this month has put a real number on what level of Lp(a) is the one to worry about. It’s 175.
What lipoprotein(a) actually is
Lp(a), pronounced “L-P little a,” is a particle in your blood that carries cholesterol. It looks almost exactly like LDL cholesterol, the so-called “bad” cholesterol you’ve heard about your whole life, with one wrinkle. Lp(a) has an extra protein wrapped around it called apolipoprotein(a). That extra protein changes how the particle behaves. It makes the particle stickier in the lining of arteries, more inflammatory, and worse at being cleared from the bloodstream.
The reason Lp(a) doesn’t show up on the basic cholesterol panel most labs run is that it has to be measured separately. The standard cholesterol panel reports total cholesterol, HDL, LDL, and triglycerides. None of those numbers tell you anything about your Lp(a). The Lp(a) test has to be ordered on its own.
Approximately one in five people walks around with elevated Lp(a). The vast majority of them have no idea, because Lp(a) causes no symptoms on its own. Your level is set by your genes, locked in at birth. Diet doesn’t change it much. Exercise doesn’t change it much. Statins don’t change it much. Once you have your number, you have it for life.
I wrote about Lp(a) in depth here if you want the full mechanism. The short version: a high Lp(a) is the genetic head start nobody wants. It’s one of the strongest non-modifiable predictors of early heart attack and aortic valve disease, and standard cholesterol treatment doesn’t bring it down.
What’s new from SCAI 2026
Researchers pooled data from three large NIH-funded clinical trials. The trial names are familiar in cardiology: ACCORD (looking at intensive diabetes treatment), PEACE (an ACE inhibitor in coronary disease), and SPRINT (intensive blood pressure control). Across the three studies, they had stored plasma samples from 20,070 patients aged 40 and older. They measured Lp(a) in all of those samples and then linked Lp(a) levels to the cardiovascular events that happened during the trials.
The headline finding is the one I want every patient to understand. Above 175 nmol/L, Lp(a) was associated with substantially higher cardiovascular risk, and that elevated risk persisted while patients were being treated aggressively with the standard medications of the day. Statins, ACE inhibitors, and blood pressure control didn’t erase it. Lp(a) above 175 was an independent driver of events.
For patients with existing heart disease, the risk signal was stronger still.
The clinical message is simple. If your Lp(a) is above 175 nmol/L, treating only your LDL cholesterol and your blood pressure leaves the original culprit untreated. You need a more aggressive plan, because the genetic risk that put you in this position hasn’t gone anywhere.
What “more aggressive” actually looks like
We don’t yet have a medication that directly lowers Lp(a) and is FDA-approved for that indication. Several are in late-stage trials, including pelacarsen and olpasiran, and we expect outcomes data over the next few years that will tell us whether dropping Lp(a) translates to fewer heart attacks. For now, the strategy in elevated Lp(a) is to drive every other cardiovascular risk factor as low as it will go.
In practice, that means:
A tighter LDL target. For most patients with established heart disease, the standard target is an LDL below 70 mg/dL. For patients with elevated Lp(a), I push for below 55, sometimes lower. The reasoning is straightforward. If you can’t yet lower the bad genetic particle, you do everything else you can to reduce the total volume of cholesterol particles damaging your arteries.
Combining cholesterol medications. A statin alone often won’t get a high-Lp(a) patient where they need to be. We add ezetimibe, then often add a PCSK9 inhibitor like Repatha or twice-yearly Leqvio. I’ve written more about how PCSK9 inhibitors work, and my Leqvio article covers the twice-yearly option in detail.
Coronary artery calcium scoring. A CAC scan is a 10-minute test that tells us how much calcified plaque is sitting in your coronary arteries already. In a patient with elevated Lp(a), the CAC score helps me figure out how much of that genetic risk has already turned into actual disease. A score in someone in their forties or fifties with high Lp(a) often pushes us toward earlier and more aggressive treatment. I covered CAC scoring in depth here.
Aspirin in the right patients. Low-dose aspirin remains useful in patients with elevated Lp(a) who are at high cardiovascular risk. The decision is individualized and I cover the trade-offs in my aspirin article.
Testing family members. Because Lp(a) is genetic, if your number is high, your first-degree relatives are at substantially elevated risk of also having elevated Lp(a). Siblings, parents, and adult children should get tested. This is an underused opportunity to find disease before symptoms.
What to ask for at your next visit
If you’ve never had your Lp(a) measured, ask for it. The 2026 ACC/AHA cholesterol guidelines now formally recommend one Lp(a) measurement in every adult, ideally early enough that the result can shape decades of prevention. The test itself is straightforward, covered by most insurance, and you only need it once. Your number doesn’t change meaningfully over your lifetime.
If you’ve already had your Lp(a) measured and it was below 75 nmol/L, you can largely set it aside. Standard cholesterol management is what matters for you.
If your Lp(a) was between 75 and 175 nmol/L, you’re in an intermediate zone. The 2026 SCAI data suggests the strongest risk signal is above 175, but the intermediate range still warrants attention to overall risk factor control.
If your Lp(a) was above 175 nmol/L, the conversation is different. You need a tighter LDL target, you likely need combination cholesterol therapy, you should consider CAC scoring if you haven’t had it, and your siblings and adult children should be tested. If you’ve already had a cardiac event, the case for aggressive treatment is stronger still.
My take
The SCAI 2026 data is the most useful Lp(a) study I’ve seen in years, because it puts a clinical threshold on a number that until now has been hard to act on. We’ve known for two decades that high Lp(a) is bad. The question was always “how high is too high, and what do I do about it.” This pooled analysis of 20,070 patients gives a real answer to the first question. 175 nmol/L is the threshold worth treating around. The second question, the one about specific Lp(a)-lowering drugs, is still in clinical trials, but everything else in our cardiovascular toolbox can be applied today.
If there’s one piece of advice I’d give every patient reading this post, it’s this: get your Lp(a) tested. It’s a one-time test that can rewrite your prevention plan, and the people most likely to benefit are exactly the ones who don’t know they’re at risk yet.